A
Aimed bio
Biotech & Life Sciences · Seoul, South Korea · Founded 2018
Innovative brain therapeutics leveraging BBB crossing technologies and precision medicine for neurodegenerative diseases MoreLess
AIMEDBIO is a pioneering company in the field of brain therapeutics, focusing on the development of treatments for neurodegenerative diseases. The company leverages its proprietary Blood-Brain Barrier (BBB) crossing technologies and precision medicine platform to identify and target brain-specific conditions. AIMEDBIO operates in the healthcare and biotechnology market, primarily serving patients suffering from brain diseases such as neuro-oncology and neurology disorders. The business model revolves around extensive research and development (R&D) pipelines, which are aimed at creating efficient and effective brain-specific immune modulators and therapeutics. Revenue is generated through the development and commercialization of these advanced treatments. The company's long-standing expertise in brain research, combined with big data analysis, positions it as a leader in the field of brain disease treatment. AIMEDBIO's commitment to innovation and scientific breakthroughs continues to drive its mission of providing optimal solutions for individual patients.
Keywords: neurodegenerative diseases, brain therapeutics, BBB crossing, precision medicine, immune modulators, neuro-oncology, neurology, big data analysis, R&D pipelines, brain-specific targets.
Company overview
Aimed bio company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2018
- Headquarters
- Seoul, South Korea
- Employees
- 16
- Open positions
- None listed
- Dealroom signal
- 83.4
- Investment activity
- 1 companies · latest Aug 2026
- Capital deployed
- $31M
- Preferred round
- SERIES B
Valuation & funding
Aimed bio funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| IPOOther financing | Dec 2025 | $59M | — | Undisclosed | — |
| LATE VCOther financing | Jun 2025 | $43M | $171M | Undisclosed | ↗ |
| SERIES BOther financing | Jul 2024 | $37M | $148M | InterVest · Samsung BioLogics · DS Asset Management · Samsung Life Science Fund | ↗ |
| EARLY VCOther financing | Sep 2023 | $0 | — | Samsung Bioepis · Samsung C&T’s Engineering & Construction · Samsung BioLogics | ↗ |
| SPINOUTOther financing | Aug 2018 | $0 | — | Samsung Medical Center | ↗ |
Financials
Revenue and workforce over time
Available revenue and workforce history. Fields without reported data are omitted.
| Year | Revenue | Growth | Employees |
|---|---|---|---|
| 2026 | $40M | 0% | 16 |
| 2025 | $40M | +302% | 15 |
| 2024 | $9.9M | +6777.3% | 11 |
| 2023 | $143K | — | 10 |
| 2022 | — | — | 13 |
| 2021 | — | — | 12 |
Growth signals
Aimed bio website traffic
Latest recorded traffic for Aimed bio is 4.6K monthly website visits, down 34.3% over the last three months. Aimed bio's team grew 6.7% over the past year.
Comparisons
Aimed bio compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Capital deployed
Aimed bio investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Talent graph
Aimed bio's talent
Source: Dealroom Talent Intelligence.
Investors
9 investors on Aimed bio's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Aimed bio has talent and traffic
team presence
In the news
Latest news about Aimed bio
Recent press, funding announcements, and product moves mentioning Aimed bio — open to read from the original sources.
Market sentiment
What the market is saying about Aimed bio
An AI-synthesized read of the highest-engagement posts about Aimed bio on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Aimed bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.